SECUKINUMAB IMPROVES SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS IN A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY USING A SUBCUTANEOUS DOSING REGIMEN (FUTURE 2)

被引：1
|
作者：
McInnes, I. B. [1 ]
Mease, P. [2 ,3 ]
Kirkham, B. [4 ]
Kavanaugh, A. [5 ]
Ritchlin, C. [6 ]
Rahman, P. [7 ]
Van der Heijde, D. [8 ]
Landewe, R. [9 ,10 ]
Conaghan, P. G. [11 ]
Gottlieb, A. B. [12 ]
Richards, H. [13 ]
Ligozio, G. [14 ]
Pricop, L. [14 ]
Mpofu, S. [13 ]
机构：
[1] Univ Glasgow, Glasgow, Lanark, Scotland
[2] Swedish Med Ctr, Seattle, WA USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Guys & St Thomas Hosp, London, England
[5] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA
[6] Univ Rochester, Med Ctr, New York, NY USA
[7] Mem Univ, St John, NF, Canada
[8] Leiden Univ, Med Ctr, Leiden, Netherlands
[9] Univ Amsterdam, Amsterdam, Netherlands
[10] Atrium Med Ctr, Amsterdam, Netherlands
[11] Univ Leeds, Leeds, W Yorkshire, England
[12] Tufts Med Ctr, Boston, MA USA
[13] Novartis Pharma AG, Basel, Switzerland
[14] Novartis Pharmaceut, E Hanover, NJ USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2015年 / 74卷
关键词：
D O I：
10.1136/annrheumdis-2015-eular.2265
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0425
引用
收藏
页码：352 / 353
页数：3
相关论文
共 50 条
  • [1] Secukinumab improves signs and symptoms of active psoriatic arthritis: Results from a phase 3 randomized, multicenter, double-blind, placebo-controlled study using a subcutaneous dosing regimen (FUTURE 2)
    Gottlieb, A. B.
    McInnes, I. B.
    Mease, P.
    Kirkham, B.
    Kavanaugh, A.
    Ligozio, G.
    Pricop, L.
    Mpofu, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S29 - S29
  • [2] Secukinumab improves active psoriatic arthritis and inhibits radiographic progression: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study
    Mease, P.
    McInnes, I. B.
    Kirkham, B.
    Kavanaugh, A.
    Rahman, P.
    Van Der Heijde, D.
    Landewe, R.
    Nash, P.
    Pricop, L.
    Yuan, J.
    Richards, H.
    Mpofu, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S29 - S29
  • [3] Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
    Zou, Hejian
    Wan, Weiguo
    Xue, Yu
    Sun, Lingyun
    Zhang, Ning
    Chen, Haiying
    Shi, Xiaofei
    Liu, Shengyun
    Chen, Lin
    Ma, Xinmei
    Wei, Hua
    Jiang, Zhenyu
    Li, Xiaomei
    Fan, Hongtao
    Li, Hongbin
    Li, Jingyang
    Wu, Rui
    Shi, Guixiu
    Zhu, Jing
    Kong, Xiaodan
    Lu, Yuewu
    Cui, Xiaojing
    Zheng, Qianning
    Bai, Xiaoyan
    Dong, Guangchao
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 5240 - 5242
  • [4] SECUKINUMAB INHIBITS RADIOGRAPHIC PROGRESSION IN PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 1)
    Van der Heijde, D.
    Landewe, R.
    Mease, P.
    McInnes, I. B.
    Conaghan, P. G.
    Pricop, L.
    Ligozio, G.
    Richards, H.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 347 - 348
  • [5] Secukinumab is effective in reducing dactylitis and enthesitis using multiple measures in patients with psoriatic arthritis: Results of a phase 3 randomized, multicenter, double-blind, placebo-controlled study (FUTURE 2)
    Mease, P.
    Kirkham, B.
    McInnes, I. B.
    Kremer, J.
    Kandala, S.
    Pricop, L.
    Mpofu, S.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S30 - S30
  • [6] Secukinumab Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: 52-Week Results from a Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial with Subcutaneous Loading and Maintenance Dosing
    Braun, Juergen
    Deodhar, Atul A.
    Sieper, Joachim
    Dougados, Maxime
    Porter, Brian
    Andersson, Mats
    Richards, Hanno
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [7] Continued Improvement of Signs and Symptoms in Patients with Active Psoriatic Arthritis: Week 52 Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study.
    Kavanaugh, Arthur
    McInnes, Iain B.
    Gottlieb, Alice B.
    Puig, Lluis
    Rahman, Proton
    Ritchlin, Christopher T.
    Li, Shu
    Wang, Yuhua
    Doyle, Mittie K.
    Mendelsohn, Alan M.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4168 - 4168
  • [8] SECUKINUMAB SIGNIFICANTLY IMPROVES SIGNS AND SYMPTOMS OF ACTIVE ANKYLOSING SPONDYLITIS: 52-WEEK DATA FROM MEASURE 2, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 TRIAL WITH SUBCUTANEOUS LOADING AND MAINTENANCE DOSING
    Sieper, J.
    Braun, J.
    Baraliakos, X.
    Baeten, D. L.
    Dougados, M.
    Emery, P.
    Deodhar, A.
    Wei, J. C. -C.
    Porter, B.
    Andersson, M.
    Mpofu, S.
    Richards, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 132 - 133
  • [9] SECUKINUMAB IS EFFECTIVE IN REDUCING DACTYLITIS AND ENTHESITIS USING MULTIPLE MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS: DATA FROM A PHASE 3 RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY (FUTURE 2)
    Kirkham, B.
    McInnes, I. B.
    Mease, P.
    Kremer, J.
    Kandala, S.
    Pricop, L.
    Mpofu, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 351 - 351
  • [10] Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing.
    McInnes, Iain B.
    Mease, Philip J.
    Kirkham, Bruce
    Kavanaugh, Arthur
    Ritchlin, Christopher T.
    Rahman, Proton
    van der Heijde, Desiree
    Landewe, Robert B. M.
    Conaghan, Philip G.
    Richards, Hanno
    Ligozio, Gregory
    Pricop, Luminita
    Mpofu, Shephard
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 (12) : 3529 - 3529
12345